Year All20262025202420232022202120202019 Jul 13, 2026 Aligos Therapeutics Announces the Completion of Enrollment in the Phase 2 B-SUPREME Study of Pevifoscorvir Sodium Under Development for the Treatment of Chronic HBV Infection Jul 06, 2026 Aligos Therapeutics Receives Upfront Payment of $25M USD from the Exclusive License Deal of Pevifoscorvir Sodium in Greater China for Chronic Hepatitis B Virus Infection May 27, 2026 Aligos Therapeutics Presents Positive Data at the EASL Congress 2026 May 13, 2026 Aligos Therapeutics Announces Ten Abstracts Accepted for Presentation at the EASL Congress 2026 May 07, 2026 Aligos Therapeutics Reports Recent Business Progress and First Quarter 2026 Financial Results Apr 30, 2026 Aligos Therapeutics to Announce 1st Quarter 2026 Financial Results on May 7, 2026 Apr 24, 2026 Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Apr 16, 2026 Aligos Therapeutics Enters into Exclusive License Deal with Xiamen Amoytop Biotech Co., Ltd. to Develop and Commercialize Pevifoscorvir Sodium in Greater China for Chronic Hepatitis B Virus Infection Apr 14, 2026 Aligos Therapeutics Announces First Interim Analysis Results from the Phase 2 B-SUPREME Study of Pevifoscorvir Sodium in Participants with Chronic Hepatitis B Virus Infection and Grant of FDA Fast Track Designation Mar 05, 2026 Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2025 Financial Results
Jul 13, 2026 Aligos Therapeutics Announces the Completion of Enrollment in the Phase 2 B-SUPREME Study of Pevifoscorvir Sodium Under Development for the Treatment of Chronic HBV Infection
Jul 06, 2026 Aligos Therapeutics Receives Upfront Payment of $25M USD from the Exclusive License Deal of Pevifoscorvir Sodium in Greater China for Chronic Hepatitis B Virus Infection
May 13, 2026 Aligos Therapeutics Announces Ten Abstracts Accepted for Presentation at the EASL Congress 2026
May 07, 2026 Aligos Therapeutics Reports Recent Business Progress and First Quarter 2026 Financial Results
Apr 16, 2026 Aligos Therapeutics Enters into Exclusive License Deal with Xiamen Amoytop Biotech Co., Ltd. to Develop and Commercialize Pevifoscorvir Sodium in Greater China for Chronic Hepatitis B Virus Infection
Apr 14, 2026 Aligos Therapeutics Announces First Interim Analysis Results from the Phase 2 B-SUPREME Study of Pevifoscorvir Sodium in Participants with Chronic Hepatitis B Virus Infection and Grant of FDA Fast Track Designation
Mar 05, 2026 Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2025 Financial Results
